Human Pathology
Volume 39, Issue 8 , Pages 1221-1228 , August 2008

Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer

  • Frederique Penault-Llorca, MD

      Affiliations

    • Centre Jean Perrin, 63011 Clermont Ferrand, France
    • Institut National de la Santé et de la Recherche Médicale (INSERM) U484, 63005 Clermont-Ferrand Cedex, France
    • Université d'Auvergne, 63001 Clermont-Ferrand Cedex 1, France
    • ,
  • Catherine Abrial, PhD

      Affiliations

    • Centre Jean Perrin, 63011 Clermont Ferrand, France
    • Institut National de la Santé et de la Recherche Médicale (INSERM) U484, 63005 Clermont-Ferrand Cedex, France
    • Corresponding Author InformationCorresponding author. Centre Jean Perrin, Bureau de Recherche Clinique, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand Cedex 1, France.
    • ,
  • Ines Raoelfils, MD

      Affiliations

    • Centre Jean Perrin, 63011 Clermont Ferrand, France
    • ,
  • Anne Cayre, PhD

      Affiliations

    • Centre Jean Perrin, 63011 Clermont Ferrand, France
    • Institut National de la Santé et de la Recherche Médicale (INSERM) U484, 63005 Clermont-Ferrand Cedex, France
    • ,
  • Marie-Ange Mouret-Reynier, MD

      Affiliations

    • Centre Jean Perrin, 63011 Clermont Ferrand, France
    • Université d'Auvergne, 63001 Clermont-Ferrand Cedex 1, France
    • ,
  • Marianne Leheurteur, MD

      Affiliations

    • Centre Jean Perrin, 63011 Clermont Ferrand, France
    • Université d'Auvergne, 63001 Clermont-Ferrand Cedex 1, France
    • ,
  • Xavier Durando, MD

      Affiliations

    • Centre Jean Perrin, 63011 Clermont Ferrand, France
    • Université d'Auvergne, 63001 Clermont-Ferrand Cedex 1, France
    • ,
  • Jean-Louis Achard, MD

      Affiliations

    • Centre Jean Perrin, 63011 Clermont Ferrand, France
    • Université d'Auvergne, 63001 Clermont-Ferrand Cedex 1, France
    • ,
  • Pierre Gimbergues, MD

      Affiliations

    • Centre Jean Perrin, 63011 Clermont Ferrand, France
    • Université d'Auvergne, 63001 Clermont-Ferrand Cedex 1, France
    • ,
  • Philippe Chollet, MD

      Affiliations

    • Centre Jean Perrin, 63011 Clermont Ferrand, France
    • Institut National de la Santé et de la Recherche Médicale (INSERM) U484, 63005 Clermont-Ferrand Cedex, France
    • Université d'Auvergne, 63001 Clermont-Ferrand Cedex 1, France
    • Centre d'Investigation Clinique, 63000 Clermont-Ferrand, France

Received 21 May 2007 ,Revised 23 October 2007 ,Accepted 7 November 2007.

References 

  1. Buchholz T, Hunt K, Whitman G, et al. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer. 2003;98:1150–1160
  2. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685
  3. Amat S, Abrial C, Penault-Llorca F, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 2005;94:255–263
  4. Costa SD, Von Minckwitz G, Raab G, et al. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol. 1999;3(Suppl 9):24–31
  5. Belembaogo E, Feillel V, Chollet P, et al. Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer. 1992;28A:896–900
  6. Chollet P, Charrier S, Brain E, et al. Clinical and pathological response to primary chemotherapy in inoperable breast cancer. Eur J Cancer. 1997;33:862–866
  7. Van Praagh I, Curé H, Leduc B, et al. Efficacy of a primary regimen combining vinorelbine, epirubicin and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. Oncologist. 2002;7:418–423
  8. Abrial C, Van Praagh I, Delva R, et al. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. Oncologist. 2005;10:242–249
  9. Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer. 2003;88:1339–1345
  10. Amat S, Mouret-Reynier MA, Penault-Llorca F, et al. Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer. Clin Breast Cancer. 2006;7:262–269
  11. Abrial C, Mouret-Reynier MA, Amat S, et al. Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers. Med Oncol. 2005;22:233–240
  12. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16:223–228
  13. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180:297–306
  14. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc. 1957;53:457–471
  15. Kuerer HM, Newman L, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469
  16. Carey LA, Metzger R, Dees EC, et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst. 2005;97:1137–1142
  17. Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002;20:1304–1310
  18. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002;86:1041–1046
  19. Eltahir A, Heys SD, Hutcheon AW, et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg. 1998;175:127–132
  20. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer; eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16:93–100
  21. Jones RL, Lakhani SR, Ring AE, et al. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer. 2006;94:358–362
  22. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650–2655

PII: S0046-8177(08)00007-5

doi: 10.1016/j.humpath.2007.11.019

Human Pathology
Volume 39, Issue 8 , Pages 1221-1228 , August 2008

Article Tools

* Image Usage & Resolution